I am thinking it's Sanofi, we shall see. The negative MS analyst estimated peak sales of the MAb they acquired through IMGN at $1.5BB and they have 2 other molecules. He estimated peak sales for Kadcyla at $6BB+ Then he went on to say IMGN execs will waste all of the money on more failed internal programs.
This morning I sent an email to the new CEO at Takeda suggesting his team take a look. I have been directly contacting IMGN BOD members to voice my displeasure with the current price among other things. IMGN needs to consider/reward their long suffering shareholders.